Augmedix, a company that say it turns natural clinician-patient conversation into medical documentation, announced on Wednesday, that Joe Marks, executive director of the Center for Machine Learning & Health at Carnegie Mellon University has been named as the company's new director.
Marks brings to the company extensive experience across such disciplines as artificial intelligence and human-in-the-loop automation. He has run the research labs at both Mitsubishi Electric and The Walt Disney Company. He has worked on DARPA-sponsored research projects for the US government, co-founded two start-ups, and has served as an advisor and consultant to the American Medical Association, all in addition to his current work at Carnegie Mellon. At Augmedix, Marks' official title will be independent director.
Manny Krakaris, chief executive officer at Augmedix, said, 'Augmedix is aggressively pursuing automation innovation in medical note documentation, data aggregation, and analysis. Joe Marks has an established record of pushing technical boundaries of artificial intelligence and machine learning, particularly within health care. We're delighted to have someone of Joe's stature join our team and apply his unique expertise to enhance our efforts in this area.'
Sobi agrees to acquire Arthrosi Therapeutics
Amgen's UPLIZNA receives US FDA approval
Innovent Biologics' mazdutide injection meets Phase 1b clinical study primary endpoint
FDA grants priority review to Bristol Myers Squibb's Opdivo regimen for advanced Hodgkin lymphoma
Physiomics secures new contract with Numab Therapeutics for preclinical antibody development
OTR Therapeutics agrees strategic collaboration and licence agreement with Zealand Pharma A/S
Privo Technologies doses first patient in first-in-human clinical trial of PRV131
Senhwa Biosciences signs clinical supply agreement with BeOne Medicines
InduPro secures strategic investment and collaboration with Sanofi to advance autoimmune therapy
Innovent Biologics reports first participant dosed in Phase 1 trial of IBI3011
D3 Bio completes USD108m Series B financing round
Hemab Therapeutics announces positive Phase 2 multiple ascending dose study results for sutacimig
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
Champions Oncology expands bioanalytical services with new technology and leadership